Literature DB >> 20408530

Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.

Sabrina Taliani1, Concettina La Motta, Laura Mugnaini, Francesca Simorini, Silvia Salerno, Anna Maria Marini, Federico Da Settimo, Sandro Cosconati, Barbara Cosimelli, Giovanni Greco, Vittorio Limongelli, Luciana Marinelli, Ettore Novellino, Osele Ciampi, Simona Daniele, Maria Letizia Trincavelli, Claudia Martini.   

Abstract

Adenosine induces glioma cell proliferation by means of an antiapoptotic effect, which is blocked by cotreatment with selective A(3) AR antagonists. In this study, a novel series of N(2)-substituted pyrazolo[3,4-d]pyrimidines 2a-u was developed as highly potent and selective A(3) AR antagonists. The most performing compounds were derivatives 2a (R(1) = CH(3) and R(2) = COC(6)H(5); K(i) 334, 728, and 0.60 nM at the human A(1), A(2A), and A(3) ARs, respectively) and 2b (R(1) = CH(3) and R(2) = COC(6)H(4)-4-OCH(3); K(i) 1037, 3179, and 0.18 nM at the human A(1), A(2A), and A(3) ARs, respectively), which counteracted the effect of the A(3) AR agonists Cl-IB-MECA and IB-MECA on human glioma U87MG cell proliferation. This effect was concentration-dependent, with IC(50) values comparable to A(3) AR binding affinity values of 2a and 2b, thereby suggesting that their effects were receptor-mediated. Furthermore, the antiproliferative activity of the new compounds was demonstrated to be mediated by the block of A(3) AR agonist activation of intracellular kinases ERK 1/2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408530     DOI: 10.1021/jm901785w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.

Authors:  Iolanda D'Alimonte; Eleonora Nargi; Mariachiara Zuccarini; Paola Lanuti; Patrizia Di Iorio; Patricia Giuliani; Lucia Ricci-Vitiani; Roberto Pallini; Francesco Caciagli; Renata Ciccarelli
Journal:  Purinergic Signal       Date:  2015-05-15       Impact factor: 3.765

2.  Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Authors:  Anke C Schiedel; Svenja K Lacher; Carsten Linnemann; Percy A Knolle; Christa E Müller
Journal:  Purinergic Signal       Date:  2013-01-29       Impact factor: 3.765

Review 3.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

Review 4.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

5.  CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Concettina La Motta; Gabriele Materazzi; Guido Bocci; Federico Da Settimo; Paolo Miccoli; Alessandro Antonelli
Journal:  Endocrine       Date:  2015-08-19       Impact factor: 3.633

6.  3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects.

Authors:  Alessia Scatena; Francesco Fornai; Maria Letizia Trincavelli; Sabrina Taliani; Simona Daniele; Isabella Pugliesi; Sandro Cosconati; Claudia Martini; Federico Da Settimo
Journal:  ACS Chem Neurosci       Date:  2011-06-10       Impact factor: 4.418

7.  Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A3 adenosine receptor.

Authors:  Barbara Cosimelli; Giovanni Greco; Sonia Laneri; Ettore Novellino; Antonia Sacchi; Simona Collina; Daniela Rossi; Sandro Cosconati; Elisabetta Barresi; Sabrina Taliani; Maria Letizia Trincavelli; Claudia Martini
Journal:  Medchemcomm       Date:  2017-11-09       Impact factor: 3.597

8.  Potent and selective A3 adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties.

Authors:  Stephanie Federico; Enrico Margiotta; Stefano Moro; Sonja Kachler; Karl-Norbert Klotz; Giampiero Spalluto
Journal:  RSC Med Chem       Date:  2020-12-14

Review 9.  Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships.

Authors:  Siew Lee Cheong; Gopalakrishnan Venkatesan; Priyankar Paira; Ramasamy Jothibasu; Alexander Laurence Mandel; Stephanie Federico; Giampiero Spalluto; Giorgia Pastorin
Journal:  Int J Med Chem       Date:  2011-03-07

10.  Crystal structure of 1,5-diethyl-3',5'-di-phenyl-1,5-di-hydro-3'H-spiro-[pyra-zolo[3,4-d]pyrimidine-4,2'-[1,3,4]thia-diazole].

Authors:  Mohammed El Fal; Youssef Ramli; El Mokhtar Essassi; Mohamed Saadi; Lahcen El Ammari
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.